Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-1 Antibody Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer: a Phase II Clinical Study

NCT05982301 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05982301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05982301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-1 Antibody Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer: a Phase II Clinical Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
February 9, 2023
Completion date
December 31, 2025
Enrollment
87 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, gastric cancer, immune checkpoint inhibitor